Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.41 |
| ▸ | FDPS | P14324 | 9/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19114877 | 1.00 | LMNA (0.65) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL29302167 | 1.00 | LMNA (0.65) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL18415057 | 1.00 | LMNA (0.65) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL2352766 | 1.00 | LMNA (0.65) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL2347979 | 1.00 | LMNA (0.65) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL19387345 | 0.98 | LMNA (0.62) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL12882141 | 0.95 | LMNA (0.59) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL21899665 | 0.93 | SMN1; SMN2 (0.57) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL2340586 | 0.92 | SMN1; SMN2 (0.55) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL28237074 | 0.91 | LMNA (0.54) | LMNAALDH1A1TSHRHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534547-B2 | Optically active compound and photosensitive resin composition | OSAKA GAS COMPANY LIMITED (JP) | 2009-05-19 | — | — | US | disclosed |
| EP-1375463-A1 | OPTICALLY ACTIVE COMPOUND AND PHOTOSENSITIVE RESIN COMPOSITION | Kansai Research Institute, Inc. (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-20030211421-A1 | Optically active compound and photosensitive resin composition | KRI, INC. (JP) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030211421-A1 | Optically active compound and photosensitive resin composition | ARCN1, RAD51, PAM | LMNA 202/4885ALDH1A1 1552/4885TSHR 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.